June 21, 2018 A framework for the assessment of novel next-generation tobacco and nicotine products with the potential to reduce health risks compared with cigarettes should integrate scientific studies incorporating nonclinical, clinical, and population studies approaches. These products should have lower emissions and exhibit reduced biological effects compared with those of cigarettes, ideally approaching those of smoking cessation. The products should also be acceptable cigarette alternatives for current smokers, while not appealing to nonsmokers or former smokers. Validating harm reduction and promoting regulatory acceptance...Acute Respiratory Toxicity | Chronic Respiratory Toxicity | Goblet Cell Hyperplasia | Pulmonary Models | Respiratory Toxicology | Tobacco | A Wallace Hayes | Christopher Proctor | e-cigarette | Erin Hill
June 21, 2018 The U.S. Food and Drug Administration has regulatory authority over tobacco products, including conventional cigarettes and next generation products (NGPs) such as e-cigarettes and tobacco heating products (THPs). There is a desire by the industry, regulators and animal protection organizations to incorporate non-animal test methods for tobacco product and NGP assessment. When assessing respiratory effects in vitro, reliable exposure systems that deliver aerosols to cellular/tissue cultures (such as human reconstructed airways or lung slices) at the air–liquid interface are needed. Using nicotine dosimetry, we report the...Acute Respiratory Toxicity | Chronic Respiratory Toxicity | Goblet Cell Hyperplasia | Pulmonary Models | Respiratory Toxicology | Tobacco | Devin Sheehan | e-cigarette | Erin Hill | Holger Behrsing